Alfonso Berrocal Jaime-rekin lankidetzan egindako argitalpenak (21)

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology

2021

  1. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 6, pp. 586-598

2019

  1. A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1754-1762

  2. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma

    Oncologist, Vol. 24, Núm. 10, pp. 1375-1383

2017

  1. Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study

    Medicine, Vol. 96, Núm. 52, pp. e9523

  2. Highlights of the season 2016-2017 by the Spanish Melanoma Group (GEM)

    Annals of Translational Medicine, Vol. 5, Núm. 19

  3. Infomelanoma 2020: An online digital application designed to assist health professionals for melanoma treatment

    Annals of Translational Medicine, Vol. 5, Núm. 19, pp. 1-9

  4. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 761-768

  5. Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM)

    Annals of Translational Medicine, Vol. 5, Núm. 19

  6. Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM)

    Annals of Translational Medicine, Vol. 5, Núm. 19

2016

  1. GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases

    Annals of Oncology, Vol. 27, pp. vi383

  2. Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14-02

    Annals of Oncology, Vol. 27, pp. vi377

  3. Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience

    Clinical and Translational Oncology, Vol. 18, Núm. 11, pp. 1147-1157

  4. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study

    Melanoma Research, Vol. 26, Núm. 3, pp. 278-283

2015

  1. Immune checkpoint inhibitors: Therapeutic advances in melanoma

    Annals of Translational Medicine, Vol. 3, Núm. 18

  2. Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma

    European Journal of Dermatology, Vol. 25, Núm. 5, pp. 392-403

2014

  1. Guidelines for biomarker testing in metastatic melanoma: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 362-373

  2. Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations

    Advances in Therapy, Vol. 31, Núm. 9, pp. 945-960

  3. Recomendaciones para la determinación de biomarcadores en el melanoma metastásico. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

    Revista Espanola de Patologia